Electroanatomic Voltage–Guided Endomyocardial Biopsy for the Diagnosis of Isolated Cardiac Sarcoidosis Authors: Katharina M. Wörgötter, Philip Dehinde, Johannes Kranlich, Tamara Bernreiter, Felicia C. Thianich, Karin Klingel, Armin Hönlinger, Franz X. Roithinger, Martin R. Grübler Published: 2026 ABSTRACT Cardiac sarcoidosis is challenging to diagnose given its heterogeneous presentation and the limited sensitivity of conventional fluoroscopy-guided endomyocardial biopsy. As a result, diagnosis is often delayed or missed entirely. Electroanatomic mapping–guided endomyocardial biopsy has emerged as a strategy to improve diagnostic yield and is, for the first time, acknowledged in the 2025 European Society of Cardiology guidelines for myocarditis and pericarditis with a Class IIa recommendation, should biopsy be indicated. We present 3 cases illustrating the diagnostic utility and limitations of electroanatomic-guided endomyocardial biopsy within a multimodal diagnostic framework for cardiac sarcoidosis. Visual SummaryDiagnostic Approach to Isolated Cardiac SarcoidosisThe visual summary illustrates the proposed diagnostic pathway for suspected isolated CS. After clinical suspicion, cardiac magnetic resonance is performed as the initial imaging modality. If findings are suggestive of CS, FDG-PET may be performed to assess inflammatory activity. In the absence of an accessible extracardiac biopsy site, EAM-guided EMB may be considered to obtain histological confirmation. CS = cardiac sarcoidosis; EAM = electroanatomic voltage map; EMB = endomyocardial biopsy; FDG-PET = 18F-fluorodeoxyglucose positron emission tomography; MRI = magnetic resonance imaging. Diagnostic Approach to Isolated Cardiac Sarcoidosis The visual summary illustrates the proposed diagnostic pathway for suspected isolated CS. After clinical suspicion, cardiac magnetic resonance is performed as the initial imaging modality. If findings are suggestive of CS, FDG-PET may be performed to assess inflammatory activity. In the absence of an accessible extracardiac biopsy site, EAM-guided EMB may be considered to obtain histological confirmation. CS = cardiac sarcoidosis; EAM = electroanatomic voltage map; EMB = endomyocardial biopsy; FDG-PET = 18F-fluorodeoxyglucose positron emission tomography; MRI = magnetic resonance imaging. Cardiac sarcoidosis (CS) is a rare inflammatory disease characterized by infiltration of noncaseating epithelioid granulomas into the myocardium. Because of its highly heterogeneous clinical presentation, diagnosis is often delayed or missed entirely. CS most commonly occurs in the context of systemic sarcoidosis, typically with pulmonary involvement, and is usually identified during subsequent evaluation for extrapulmonary involvement.1,2 In rare cases however, CS may present as an isolated cardiac manifestation, in which diagnosis is particularly challenging. Expert consensus criteria have been proposed for the diagnosis of CS, however their diagnostic accuracy remains limited.3, 4, 5 Diagnostic evaluation has traditionally relied on advanced imaging modalities, including cardiac magnetic resonance (CMR) and 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET), given the limited sensitivity of conventional fluoroscopy-guided endomyocardial biopsy (EMB), despite EMB representing the gold standard for definitive diagnosis.4,5 More recently, electroanatomic voltage mapping (EAM)–guided EMB has been increasingly employed in selected case series and small studies. Accordingly, the 2025 European Society of Cardiology guidelines on myocarditis and pericarditis acknowledge this approach and recommend the use of EAM guidance (Class IIa) when EMB is pursued as part of the diagnostic strategy in patients with suspected CS. Here, we present 3 patients in whom a diagnosis of CS was established using EAM-guided EMB.Take-Home Messages•Isolated cardiac sarcoidosis exhibits a heterogeneous clinical presentation and, despite its rarity, should be considered in patients when imaging or electrophysiological findings raise suspicion.•Electroanatomic-guided endomyocardial biopsy may improve diagnostic certainty and is best used within a multimodal diagnostic framework incorporating cardiac magnetic resonance imaging and FDG-PET. Take-Home Messages •Isolated cardiac sarcoidosis exhibits a heterogeneous clinical presentation and, despite its rarity, should be considered in patients when imaging or electrophysiological findings raise suspicion.•Electroanatomic-guided endomyocardial biopsy may improve diagnostic certainty and is best used within a multimodal diagnostic framework incorporating cardiac magnetic resonance imaging and FDG-PET. •Isolated cardiac sarcoidosis exhibits a heterogeneous clinical presentation and, despite its rarity, should be considered in patients when imaging or electrophysiological findings raise suspicion. Isolated cardiac sarcoidosis exhibits a heterogeneous clinical presentation and, despite its rarity, should be considered in patients when imaging or electrophysiological findings raise suspicion. •Electroanatomic-guided endomyocardial biopsy may improve diagnostic certainty and is best used within a multimodal diagnostic framework incorporating cardiac magnetic resonance imaging and FDG-PET. Electroanatomic-guided endomyocardial biopsy may improve diagnostic certainty and is best used within a multimodal diagnostic framework incorporating cardiac magnetic resonance imaging and FDG-PET. Procedural Details All procedures were performed using endocavitary EAM acquired with a high-density grid mapping catheter (EnSite NavX, Abbott). EAM included 3-dimensional reconstruction of the left ventricle (LV) and/or right ventricle (RV) and intracardiac electrogram recording to identify regions of low bipolar voltage consistent with abnormal myocardium. Tissue samples were obtained via right femoral venous access using a disposable bioptome advanced through a steerable sheath and integrated with the EAM system to guide it to the area of interest. The bioptome tip was directly visualized in the 3-dimensional mapping system. In cases requiring LV sampling, a transseptal approach was employed. Low-voltage areas were defined by bipolar voltage amplitudes <0.5 mV. Intracardiac echocardiography was not routinely used at our center for EMB guidance. Transesophageal echocardiography is used on a case-by-case basis; however, it was not used in the present cases. Biopsies were performed under fluoroscopic guidance using anatomical landmarks to avoid critical structures, including the subvalvular apparatus. No procedural complications occurred during the herein presented cases. Case 1 A previously healthy 44-year-old woman without relevant medical or family history presented to the emergency department with recurrent palpitations and presyncope. Symptoms had recurred intermittently for several months before emergency services were contacted during one episode. A prehospital 12-lead electrocardiogram (ECG) documented a hemodynamically tolerated, monomorphic wide QRS tachycardia, consistent with ventricular tachycardia, which subsequently terminated spontaneously. A follow-up 12-lead ECG showed no features suggestive of structural heart disease. Transthoracic echocardiography (TTE) was normal, and serial measurements of high-sensitivity troponin T remained within normal limits. In the absence of evidence for structural heart disease, the patient underwent an electrophysiological study with planned ablation for suspected idiopathic fascicular ventricular tachycardia. Ventricular arrhythmias were inducible, however, ablation was unsuccessful. She was discharged with a working diagnosis of fascicular ventricular tachycardia and prescribed verapamil with a “pill in the pocket” approach. Over the following months, the patient experienced recurrent symptomatic ventricular arrythmias documented by a smartwatch, all terminating without the need for cardioversion and without syncope, but marked dizziness was reported. She subsequently sought a second opinion and was scheduled for a CMR and repeat electrophysiological study. CMR imaging revealed extensive late gadolinium enhancement (LGE) involving the anterior septum, anterior left ventricular LV wall, and RV, with a pattern suggestive of CS, including the characteristic “shepherd's hook” sign (Figure 1B). Subsequent FDG-PET demonstrated intense metabolic activity in the anterior septum (Figure 1C). As no accessible extracardiac lymph nodes were identified for biopsy, EMB was pursued. EAM identified low-voltage areas (<0.5 mV) within the septal and anterior regions. Initial mapping of the RV demonstrated septal low-voltage zones, followed by LV mapping revealing similar abnormalities (Figure 1A). Six biopsies were obtained from each ventricle, demonstrating noncaseating granulomas and confirming CS.Figure 1Imaging and Electroanatomic Voltage Map: Case 1(A) Electroanatomic voltage map of both ventricles (LV and RV) demonstrating extensive low-voltage areas extending from the septum toward the anterior wall. The heterogeneous scar pattern may help explain the high burden of ventricular arrhythmias. (B) CMR PSIR-LGE imaging (short-axis view). Extensive LGE typical for cardiac sarcoidosis, showing the “shepherd's hook sign” with enhancement extending from the septum into the RV free wall. (C) FDG-PET showing focal FDG uptake in the basal septum, a typical site of involvement in CS. CMR = cardiac magnetic resonance; CS = cardiac sarcoidosis; FDG-PET = 18F-fluorodeoxyglucose positron-emission tomography; LGE = late gadolinium enhancement; LV = left ventricle; PSIR = phase-sensitive inversion recovery; RV = right ventricle. Imaging and Electroanatomic Voltage Map: Case 1 (A) Electroanatomic voltage map of both ventricles (LV and RV) demonstrating extensive low-voltage areas extending from the septum toward the anterior wall. The heterogeneous scar pattern may help explain the high burden of ventricular arrhythmias. (B) CMR PSIR-LGE imaging (short-axis view). Extensive LGE typical for cardiac sarcoidosis, showing the “shepherd's hook sign” with enhancement extending from the septum into the RV free wall. (C) FDG-PET showing focal FDG uptake in the basal septum, a typical site of involvement in CS. CMR = cardiac magnetic resonance; CS = cardiac sarcoidosis; FDG-PET = 18F-fluorodeoxyglucose positron-emission tomography; LGE = late gadolinium enhancement; LV = left ventricle; PSIR = phase-sensitive inversion recovery; RV = right ventricle. Leading clinical presentation: Recurrent ventricular arrhythmias. Key diagnostic findings: Typical CMR and FDG-PET findings, characteristic EAM substrate, EMB positive for CS. Follow-up: Six- and 12-month FDG-PET follow-up showed no cardiac uptake, CMR demonstrated stable scar burden, and prednisolone was discontinued. After successful immunosuppression, a repeat ventricular tachycardia ablation was successful, and the patient is clinically stable without implantable cardioverter-defibrillator shocks; yearly CMRs show a stable scar burden. She remains on methotrexate 15 mg/wk for 3 years. Case 2 A 41-year-old man underwent a routine medical examination by his general practitioner, during which an atypical right bundle branch block and T-wave inversions in multiple leads were detected on ECG (Figure 2C). Initial laboratory evaluation revealed mildly elevated cardiac biomarkers, including troponin T and creatine kinase. Except for bronchial asthma, the patient had no prior medical conditions and remained asymptomatic. TTE demonstrated ventricular hypertrophy, with a maximal interventricular septal thickness of 22 mm. To exclude coronary artery disease and RV pathology, including arrhythmogenic RV cardiomyopathy and hypertrophic cardiomyopathy, stress CMR was performed, which showed extensive myocardial scarring and edema involving both ventricles. A repeat CMR was subsequently conducted to confirm these findings. LGE was extensive within the LV and extended well into the RV, demonstrating the characteristic “shepherd's hook” pattern (Figure 2B). Native T1 and T2 mapping values were both elevated. In addition, focal wall thickening and akinesia were identified in the basal anteroseptal to anterior segments. Subsequent FDG-PET revealed intense metabolic activity in the corresponding regions, with multifocal FDG uptake and a SUVmax exceeding 13 in the basal septum. No extracardiac organ involvement was detected. Given the isolated cardiac manifestation, EMB was performed under EAM guidance. EAM included a 3-dimensional reconstruction of the RV, which identified low-voltage areas and an extensive septal scar extending from the basal to midventricular segments (Figure 2A). A total of 12 biopsy samples were obtained from low-voltage regions and adjacent border zones. Histopathological examination demonstrated noncaseating epithelioid granulomas, establishing the diagnosis of CS (Figures 3A and 3B).Figure 2CMR, Electrocardiogram, and Electroanatomic Voltage Map: Case 2(A) Electroanatomic voltage map of the RV demonstrating extensive low-voltage areas along the interventricular septum extending from the basal to the midventricular level. The scar burden appeared extensive yet relatively homogeneous, which may partly explain the absence of clinically manifest arrhythmias. Accordingly, no VT was inducible during electrophysiological study. (B) Unipolar voltage map of the RV also showing some low-voltage areas. Corresponding CMR images show extensive epicardial LGE throughout the RV. (C) PSIR-LGE (short-axis). Recurrent “shepherd's hook” pattern, demonstrating the same characteristic septal-to-RV enhancement seen in Figure 1, pathognomonic for CS. (D) Electrocardiogram demonstrating atypical right bundle branch block with T-wave inversions in multiple leads. CS = cardiac sarcoidosis; LGE = late gadolinium enhancement; PSIR = phase-sensitive inversion recovery; RV = right ventricle; VT = ventricular tachycardia.Figure 3Histological Findings in Case 2(A) Noncaseating epithelioid granuloma (Giemsa stain). (B) MHC-II–positive multinucleated giant cells and macrophages. (C) CD68-positive macrophages and multinucleated giant cells. CMR, Electrocardiogram, and Electroanatomic Voltage Map: Case 2 (A) Electroanatomic voltage map of the RV demonstrating extensive low-voltage areas along the interventricular septum extending from the basal to the midventricular level. The scar burden appeared extensive yet relatively homogeneous, which may partly explain the absence of clinically manifest arrhythmias. Accordingly, no VT was inducible during electrophysiological study. (B) Unipolar voltage map of the RV also showing some low-voltage areas. Corresponding CMR images show extensive epicardial LGE throughout the RV. (C) PSIR-LGE (short-axis). Recurrent “shepherd's hook” pattern, demonstrating the same characteristic septal-to-RV enhancement seen in Figure 1, pathognomonic for CS. (D) Electrocardiogram demonstrating atypical right bundle branch block with T-wave inversions in multiple leads. CS = cardiac sarcoidosis; LGE = late gadolinium enhancement; PSIR = phase-sensitive inversion recovery; RV = right ventricle; VT = ventricular tachycardia. Histological Findings in Case 2 (A) Noncaseating epithelioid granuloma (Giemsa stain). (B) MHC-II–positive multinucleated giant cells and macrophages. (C) CD68-positive macrophages and multinucleated giant cells. Leading clinical presentation: Incidental finding in an asymptomatic patient. Key diagnostic findings: Typical CMR and FDG-PET findings, characteristic EAM substrate, EMB positive for CS. Follow-up: Six-month FDG-PET showed no uptake, and the wall-thickening regressed both on CMR and TTE. After tapering and discontinuation of prednisolone, he remains stable asymptomatic without clinical events on methotrexate 20 mg/wk for 1 year. Case 3 A 52-year-old Caucasian man was referred to the emergency department by his primary care physician because of exertional chest discomfort, progressive decline in physical performance over several months, and an abnormal resting ECG. His past medical and surgical history was unremarkable, with no family history of premature heart disease or sudden cardiac death. He denied any active or previous drug abuse and works as a police officer in a tactical unit. Physical examination demonstrated mildly dilated jugular veins, but no leg edema or pulmonary congestion. A mild holosystolic murmur was noted. The initial ECG demonstrated second-degree atrioventricular block (Mobitz type I) and frequent ventricular ectopic beats. TTE revealed a severely reduced LV ejection fraction of approximately 30%, consistent with dilated cardiomyopathy, along with moderate mitral regurgitation. To exclude ischemic heart disease, coronary angiography was performed and demonstrated unobstructed coronary arteries. After consultation with the heart failure team, CMR was recommended and performed 6 days after presentation. CMR showed severe global LV systolic dysfunction with diffuse hypokinesis and akinesis, predominantly involving the basal inferoseptal to midventricular segments. These regions exhibited myocardial thinning and LGE, suggestive of fibrotic or inflammatory myocardial involvement (Figure 4C). Based on the CMR findings, CS was suspected. Genetic testing was additionally ordered to exclude pathogenic variants in arrhythmogenic cardiomyopathy associated genes. Further evaluation with FDG-PET demonstrated cardiac involvement with increased uptake in the apical septum (SUVmax: 9), supporting the suspected diagnosis (Figures 4A and 4B). The patient underwent EAM-guided EMB with RV mapping, which demonstrated extensive low-voltage areas involving the basal and apical septum (Figure 4D). A total of 5 targeted biopsy specimens were obtained from these regions, however histopathological analysis was nondiagnostic. An endobronchial ultrasound–guided lymph node biopsy performed during the diagnostic work-up was likewise negative. Given the persistently high clinical suspicion, the negative genetic test, and the typical scaring in the RV septum, mediastinoscopy via suprasternal access with sampling of mediastinal lymph nodes was undertaken. Histopathological examination confirmed noncaseating granulomas, thereby fulfilling the Heart Rhythm Society diagnostic criteria for CS.Figure 4Imaging and Electroanatomic Voltage Map: Case 3(A and B) FDG-PET images showing increased glucose metabolism in the interventricular septum and bilateral hilar lymph nodes. (C) CMR demonstrating LGE in the interventricular septum. (D) Electroanatomic voltage map of the RV demonstrating extensive low-voltage areas involving the basal and apical septum. Although EMB was negative, the voltage pattern was comparable to those observed in biopsy-proven CS. CMR = cardiac magnetic resonance; CS = cardiac sarcoidosis; EMB = endomyocardial biopsy; FDG-PET = 18F-fluorodeoxyglucose positron emission tomography; LGE = late gadolinium enhancement; RV = right ventricle. Imaging and Electroanatomic Voltage Map: Case 3 (A and B) FDG-PET images showing increased glucose metabolism in the interventricular septum and bilateral hilar lymph nodes. (C) CMR demonstrating LGE in the interventricular septum. (D) Electroanatomic voltage map of the RV demonstrating extensive low-voltage areas involving the basal and apical septum. Although EMB was negative, the voltage pattern was comparable to those observed in biopsy-proven CS. CMR = cardiac magnetic resonance; CS = cardiac sarcoidosis; EMB = endomyocardial biopsy; FDG-PET = 18F-fluorodeoxyglucose positron emission tomography; LGE = late gadolinium enhancement; RV = right ventricle. Leading clinical presentation: Heart failure. Key diagnostic findings: Typical CMR and FDG-PET findings, characteristic EAM substrate, EMB negative for CS, extracardiac lymph node biopsy positive for sarcoidosis. Follow-up: Six-month follow-up FDG-PET showed no cardiac uptake, and the extensive scar burden on CMR remained stable. One heart failure hospitalization and one appropriate implantable cardioverter-defibrillator shock for ventricular fibrillation occurred within the 2-year follow-up period. An additional FDG-PET after each event showed no cardiac uptake. He remained on methotrexate 15 mg/wk, guideline-directed medical therapy for heart failure with reduced ejection fraction, and was temporarily on amiodarone. At his last clinical follow-up, he was in NYHA functional class II status. After 6 months of discontinuation of amiodarone, the patient suffered sudden cardiac death while on a walk in the forest on his own without network coverage. No prodromal arrhythmias were detected by telemonitoring before the event, and the exact cause of death remains unknown. Discussion This case series highlights the diagnostic role of EAM-guided EMB in CS. EAM-guided EMB proved feasible and safe and enabled histological confirmation of CS in selected patients, supporting its role as an adjunctive tool within a multimodal diagnostic pathway. In 2 of the 3 cases, EAM-guided EMB resulted in histological confirmation of CS. In case 3, EMB remained nondiagnostic despite extensive septal low-voltage areas, highlighting current limitations of EAM-guided EMB and the complementary diagnostic value of electroanatomic and imaging findings when interpreted within the appropriate clinical context. Despite such technical advances, the sensitivity of EMB still remains limited, raising the question of under which conditions diagnostic yield is maximized. Ammirati et al6 demonstrated that EMB yield is influenced by several factors, including timing, procedural technique, biopsy location, and—most importantly—clinical pretest probability. Although derived primarily from cohorts with suspected myocarditis, these principles are broadly applicable to EMB. Timing is a critical determinant of EMB success. Given the dynamic disease course of CS with alternating inflammatory and fibrotic phases,7 EMB may be more likely to detect noncaseating granulomas when performed during active inflammation, whereas biopsies obtained during quiescent stages may be nondiagnostic. Imaging markers of active disease, including extensive LGE, elevated T1 and T2 relaxation times on CMR, and focal myocardial FDG uptake on FDG-PET, appear particularly useful for identifying patients most likely to benefit from EMB. Importantly, prior initiation of immunosuppressive treatment may reduce diagnostic yield by suppressing inflammatory activity. Technical aspects of EAM-EMB also play a central role. Bipolar voltage mapping is effective in identifying focal areas of low voltage corresponding to scarred or diseased myocardium.8 However, some evidence suggests that unipolar mapping may detect more diffuse or intramural abnormalities that are not apparent on bipolar mapping alone.8,9 Also, respiration may be a confounding factor, but in our case all cases were performed using gating to reduce motion artifacts from breathing. Current evidence suggests that unipolar voltage abnormalities may correspond to regions of active inflammation even in the absence of overt scar on CMR.9 Consequently, a combined bipolar-unipolar EAM approach may provide a more comprehensive assessment of the myocardial substrate and improve biopsy targeting in CS. The anatomical site and number of biopsy samples further influence diagnostic yield. CS often involves the interventricular septum in a patchy distribution, with healthy myocardium interspersed between diseased regions.9 Restricting sampling to a single ventricle may therefore result in missed diagnoses. Biventricular biopsy has been shown to improve diagnostic sensitivity, in part because of broader myocardial coverage and increased tissue acquisition.10 Ultimately, the diagnostic success of EMB in CS depends heavily on appropriate patient selection. High pretest probability, supported by concordant multimodal imaging findings, substantially increases the likelihood of histological confirmation. One imaging modality alone is generally insufficient to establish the diagnosis. EMB should therefore be integrated into a comprehensive diagnostic framework combining CMR, FDG-PET, and EAM rather than being used as an isolated test. Diagnosing CS remains challenging, partly because of inconsistencies among established diagnostic criteria, with the Heart Rhythm Society criteria requiring histological confirmation, unlike the Japanese Circulation Society criteria. Particularly in cases with discordant imaging findings or limited agreement between diagnostic frameworks, EAM-guided EMB may provide important diagnostic clarification by confirming CS or identifying a potential mimic. All 3 cases fulfilled the Japanese Circulation Society criteria for CS (Table 1). Case 3 additionally met Heart Rhythm Society criteria after a negative EMB, with subsequent confirmation of noncaseating granulomas on lymph node biopsy. However, the broad nature of the Japanese Circulation Society criteria may limit specificity, especially in isolated CS. Conditions such as arrhythmogenic cardiomyopathy can present with overlapping clinical and imaging features, and may fulfill similar diagnostic frameworks.4 Histological confirmation therefore remains important, particularly in view of potential adverse effects of immunosuppressive therapy. However, whenever possible, extracardiac biopsy should be preferred, especially when EAM-guided EMB is not available.Table 1Summary of All 3 Cases and Their Fulfillment of HRS, JCS, and WASOG Criteria for Cardiac Sarcoidosis Excluding Endomyocardial Biopsy ResultsCriterionCase 1Case 2Case 3HRSNoNoYesJCSYesYesYesWASOGNoNoYesBoth HRS and WASOG criteria require histological confirmation in at least 1 organ. Only case 3 demonstrated extracardiac involvement (lymph node).HRS = Heart Rhythm Society; JCS = Japanese Circulation Society; WASOG = World Association of Sarcoidosis and Other Granulomatous Disorders. Table 1Summary of All 3 Cases and Their Fulfillment of HRS, JCS, and WASOG Criteria for Cardiac Sarcoidosis Excluding Endomyocardial Biopsy ResultsCriterionCase 1Case 2Case 3HRSNoNoYesJCSYesYesYesWASOGNoNoYesBoth HRS and WASOG criteria require histological confirmation in at least 1 organ. Only case 3 demonstrated extracardiac involvement (lymph node).HRS = Heart Rhythm Society; JCS = Japanese Circulation Society; WASOG = World Association of Sarcoidosis and Other Granulomatous Disorders. Summary of All 3 Cases and Their Fulfillment of HRS, JCS, and WASOG Criteria for Cardiac Sarcoidosis Excluding Endomyocardial Biopsy Results Both HRS and WASOG criteria require histological confirmation in at least 1 organ. Only case 3 demonstrated extracardiac involvement (lymph node). HRS = Heart Rhythm Society; JCS = Japanese Circulation Society; WASOG = World Association of Sarcoidosis and Other Granulomatous Disorders. Beyond diagnostic considerations, this case series highlights the clinical heterogeneity of CS. Presentations ranged from ventricular arrhythmias to minor asymptomatic conduction abnormalities and heart failure at a relatively young age. This variability contributes to delayed or missed diagnosis. Although CS is rare, its different manifestations warrant consideration in selected clinical scenarios, particularly when imaging or electrophysiological findings are suggestive. Conclusions In summary, EAM-guided EMB represents a valuable diagnostic tool in carefully selected patients with suspected CS. Optimizing timing, imaging-based patient selection, mapping strategy, and biopsy technique is essential to maximize diagnostic yield while maintaining procedural safety. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Equipment List•Advisor HD Grid mapping catheter (Abbott)•Disposable bioptome (Bipal, Biosense Webster)•Steerable sheath (Agilis NxT, St Jude Medical)•Magnetom Aera 1.5-T magnetic resonance (Siemens)•Discovery IQ Gen 2 PET/CT system (GE HealthCare) Equipment List•Advisor HD Grid mapping catheter (Abbott)•Disposable bioptome (Bipal, Biosense Webster)•Steerable sheath (Agilis NxT, St Jude Medical)•Magnetom Aera 1.5-T magnetic resonance (Siemens)•Discovery IQ Gen 2 PET/CT system (GE HealthCare) •Advisor HD Grid mapping catheter (Abbott) Advisor HD Grid mapping catheter (Abbott) •Disposable bioptome (Bipal, Biosense Webster) Disposable bioptome (Bipal, Biosense Webster) •Steerable sheath (Agilis NxT, St Jude Medical) Steerable sheath (Agilis NxT, St Jude Medical) •Magnetom Aera 1.5-T magnetic resonance (Siemens) Magnetom Aera 1.5-T magnetic resonance (Siemens) •Discovery IQ Gen 2 PET/CT system (GE HealthCare) Discovery IQ Gen 2 PET/CT system (GE HealthCare)